Description Semgo 7mg (Semaglutide) Trusted Oral Treatment for Diabetes & Weight Management Semgo 7mg (Semaglutide) is a breakthrough oral therapy for adults living with Type 2 Diabetes Mellitus (T2DM) and related metabolic conditions
This was further advanced in FINEARTS-HF (20242025), which addressed HFpEF challenges by reducing the composite of CV death and HF hospitalization by 16% (HR 0.84, 95% CI 0.740.95, p = 0.003), HF hospitalization by 18% (HR 0.82, 95% CI 0.710.94), CV death by 7% (HR 0.93, 95% CI 0.781.11), and total HF events by 18% (HR 0.82, 95% CI 0.710.94)
Will managing side effects help improve treatment results
The FDA has also approved two GLP-1 diabetes drugs, Bydureon BCISE and Trulicity, for patients 10 y age and older
Whether youre considering retatrutide or tirzepatide, well guide you toward the best choice for your unique needs
Based on your consent, we may share information about your website interactions (e.g., pages viewed, products interacted with) with advertising platforms such as Google and Meta for the purpose of creating advertising audiences and personalising ads across Vision Healthcare brands